https://www.lfts.no/nyheter/72/collegium-pharmaceutical-oker-inntektsforventninger-etter-sterke-resultater/0.22025-08-11T09:30:18+01:00https://www.lfts.no/forskning/69/forskere-ved-uit-for-tidlig-a-konkludere-om-helseeffektene-av-isbading/0.22025-08-08T16:44:46+01:00https://www.lfts.no/okonomi/66/recursion-pharmaceuticals-rapporterer-storre-tap-enn-forventet-i-andre-kvartal-men-overgar-inntektsprognoser/0.22025-08-05T17:58:53+01:00https://www.lfts.no/nyheter/63/farmasoytisk-bransje-viktige-endringer-og-avtaler/0.22025-07-23T16:55:53+01:00https://www.lfts.no/nyheter/60/uro-i-den-globale-legemiddelindustrien-endrede-rammer-usikker-framtid-og-strategiske-omstillinger/0.22025-07-18T18:56:11+01:00https://www.lfts.no/forskning/57/maja-brukte-sparepengene-pa-adhd-diagnose-ble-avvist-i-det-offentlige/0.22025-07-18T15:06:03+01:00https://www.lfts.no/okonomi/54/novo-nordisk-inngar-samarbeid-med-weightwatchers-og-satser-pa-kunstig-intelligens-i-kampen-mot-fedme/0.12025-06-27T09:11:54+01:00https://www.lfts.no/nyheter/51/alvorlige-mangler-avdekket-i-navs-telefontjenester/0.12025-06-26T11:44:43+01:00https://www.lfts.no/nyheter/48/saudi-arabias-legemiddelmarked-forventes-a-na-117-milliarder-usd-innen-2033/0.12025-06-10T16:00:05+01:00https://www.lfts.no/forskning/45/ny-omfattende-studie-avslorer-kobling-mellom-ultraprosessert-mat-og-alvorlige-helseplager/0.12025-06-10T10:06:13+01:00https://www.lfts.no/okonomi/42/aft-pharmaceuticals-rapporterer-arsresultater-for-2024-2025/0.12025-05-22T05:03:16+01:00https://www.lfts.no/nyheter/39/sal-av-ozempic-pa-kvit-resept-blir-stansa-skal-prioriterast-til-diabetespasientar/0.12025-05-21T13:01:31+01:00https://www.lfts.no/forskning/36/ani-pharmaceuticals-melder-rekordresultater-for-forste-kvartal-2025-og-oppjusterer-helarsprognose/0.12025-05-09T15:45:48+01:00https://www.lfts.no/nyheter/33/myndighetene-strammer-inn-bruken-av-ozempic-kun-for-diabetespasienter/0.12025-05-09T08:59:58+01:00https://www.lfts.no/okonomi/30/shanghai-pharmaceuticals-investerer-i-ny-oppkjopsfond-for-biomedisin/0.12025-04-14T16:14:33+01:00https://www.lfts.no/nyheter/27/ny-studie-mounjaro-viser-storre-effekt-enn-ozempic-ved-vektnedgang/0.12025-04-14T10:36:04+01:00https://www.lfts.no/nyheter/24/fda-fastholder-skifte-bort-fra-dyreforsok-recursion-pharmaceuticals-aksjen-stiger-kraftig/0.12025-04-11T16:25:05+01:00https://www.lfts.no/livsstil/21/sterke-fundamenter-bak-kursfallet-har-markedet-undervurdert-amphastar-pharmaceuticals/0.12025-04-11T13:56:30+01:00https://www.lfts.no/nyheter/18/imbria-pharmaceuticals-sikrer-575-millioner-dollar-i-serie-b-finansiering-og-utnevner-ny-administrerende-direktor/0.12025-04-10T16:38:01+01:00